Another strong negative TF shown here is KLF5, closely co-aligned with RUNX1. KLF5 has recently been identified as a key negative regulator in ischemic cardiomyopathy in mouse and human hearts (62, 63) and has been suggested as a potential therapeutic target for drug development. Here, TF is linked to ischemic cardiomyopathy.